尼洛替尼治疗慢性粒细胞白血病引起的血管不良事件研究进展

Research progress of vascular adverse events induced by nilotinib treatment for chronic myelogenous leukemia

尼洛替尼是第二代酪氨酸激酶抑制剂,主要用于慢性粒细胞白血病慢性期或加速期对伊马替尼耐药或不耐受的患者。尼洛替尼引起治疗相关血管不良事件(VAEs)的概率大于伊马替尼,表现为外周动脉闭塞性疾病、冠状动脉狭窄、脑缺血等,严重者可危及生命。肥胖、高血压、糖尿病、高脂血症等是引发VAEs的危险因素。治疗前对患者进行综合评估,正确选择最优治疗药物,治疗过程中监测VAEs危险因素并及早干预是非常重要的。

Nilotinib is a second-generation tyrosine kinase inhibitor. It is mainly used for patients with imatinib-resistant or intolerant chronic myeloid leukemia in chronic phase or accelerated phase. The probability of treatment- related vascular adverse events （VAEs） caused by nilotinib is higher than imatinib, which manifested as peripheral arterial occlusive disease, coronary artery stenosis, cerebral ischemia and so on, and severe cases may be life threatening. There are some risk factors of VAEs, such as obesity, hypertension, diabetes, hyperlipidemia and so on. It is very important to do comprehensive assessment before treatment, choose the best drugs, monitor the risk factors of VAEs and do early intervention.